The healthcare giant could follow up its $16.6 billion acquisition of Abiomed with another deal for a heart device company, the WSJ reported Tuesday.
The healthcare giant could follow up its $16.6 billion acquisition of Abiomed with another deal for a heart device company, the WSJ reported Tuesday.